Institut Jean Paoli & Irène Calmettes;Centre National de la Recherche Scientifique (CNRS);INSERM (Institut National de la Santé et de la Recherche Médicale);Université d'Aix Marseille
发明人:
申请号：
EP18717059.2
公开号：
EP3610264A1
申请日:
2018.04.12
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The invention relates to methods for predicting the survival time of patients suffering from pancreatic ductal adenocarcinoma (PDA) and methods for the treatment of PDA. The inventors investigated the role of Pancreatitis Associated Protein (PAP/REG3A) as prognostic marker associated with PDA, evaluated its implication in PDA associated nervous system alterations (peri-neural invasion (PNI)) and its impact on PDAs' patients survival. Using an exvivo assay, they determined its influence on PNI and correlated it with the prognostic value of PAP/REG3A as a circulating biomarker. They demonstrated that PAP/REG3A enhance cancer cells migration and invasion abilities. By activating JAK/STAT signaling pathways, PAP/REG3A favors PNI, known to be associated with relapse after surgery. They also analyzed the level of PAP/REG3A in serum from healthy donors or patients with PDA from three different cohorts and demonstrate that PAP/REG3A is a biomarker of shorter survival as well as poor surgical outcomes with reduced disease-free survival. Thus, the invention relates to a method for predicting the survival time of a patient suffering from PDA and REG3A inhibitors for use in the treatment of PDA.
